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The objective of this study was to describe the reported diabetes mellitus (DM) prevalence rates of the 20–79-year-old population in
Colombia from 2009 to 2012 reported by the healthcare system. Information on number of patients treated for DMwas obtained by
the Integral Information System of Social Protection (SISPRO), the registry of theMinistry of Health and Social Protection, and the
High Cost Account (CAC), an organization to trace high expenditure diseases. From both sources age-standardized reported DM
prevalence rates per 100.000 inhabitants from 2009 to 2012 were calculated. Whereas the reported DM prevalence rates of SISPRO
revealed an increase from 964/100.000 inhabitants (2009) to 1398/100.000 inhabitants in 2012 (mean annual increase 141/100.000;
p value: 0.001), the respective rates in the CAC register were 1082/100.000 (2009) and 1593/100.000 in 2012 (mean annual increase
165/100.000; p value: 0.026). The number of provinces reporting not less than 19% of the highest national reported DM prevalence
rates (1593/100.000) increased from two in 2009 to ten in 2012. Apparently, the registries and the information retrieving system
have been improved during 2009 and 2012, resulting in a greater capacity to identify and report DM cases by the healthcare system.
1. Introduction
Diabetes mellitus (DM) is one of the fastest growing public
health problems imposing a high burden on DM patients
and high financial burden on healthcare systems. Recent
estimates of the International Diabetes Federation (IDF)
predicted that the number of adults with diabetes is expected
to rise worldwide from 366 million in 2011 to 552 million
by 2030 [1]. The last Colombian National Health Survey in
2007 revealed a DM prevalence of 3.5% in the Colombian
population 18–69 years of age according to participant self-
report [2]. However, according to the IDF there were 2.1
million DM cases in Colombia corresponding to a DM
prevalence of 7.05% in 2013 for the 20–79 year-old population
[1].
It has to be kept in mind that there is a remarkable
gap between people diagnosed with DM and those receiving
treatment. It has been shown that only approximately 50%
of the people diagnosed with DM receive medical care [3,
4]. Currently, no national register exists for DM patients
in Colombia. However, for the last six years, two official
registers have been developed in Colombia to track the
number of DM—and other relevant diseases—cases that
demand healthcare attention [5–7]. These registers use the
available information provided by the healthcare providers
and insurers. Nevertheless, no intent has yet been made to
analyze the existing information in order to see whether
there are changes in the access to DM treatment within the
healthcare system during the past years. Furthermore, it is
important for the primary healthcare system to monitor the
number of DMpatients receiving treatment on a regular basis
to evaluate its capacity to detect new DM cases and to follow
up whether it is capable to reduce the gap between diagnosed
DM cases and those receiving medical care.
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The aim of this study was to describe the reported
DM prevalence rates of the 20–79-year-old population in
Colombia during 2009 and 2012 reported by the official
information sources of the healthcare system.
2. Material and Methods
Information on number of patients withDMas primary diag-
nosis in the population of 20–79 years of age was obtained
by the Integral Information System of Social Protection
(SISPRO) and theHighCostAccount (CAC), an organization
to trace high expenditure diseases. The SISPRO is a register
developed by the Colombian Ministry of Health and Social
Protection which offers consolidated data from the health-
care services demand in Colombia. All healthcare providers
(hospitals and healthcare centers) are by law obliged to send
informationusing the ICD-10 code of the primary diagnostics
of all patients placed in the SISPRO register; thus, covers the
entire Colombian population that demands services within
Social Security Health System. The SISPRO register is fed
by different information sources of healthcare service data
after careful validation of each. Data submitted to the SISPRO
register is subject to continuous quality control testing [5, 6].
The data received is cross-checked against other information
sources (such as population census, national health surveys,
or other administrative registers) before being integrated into
the SISPRO register. If inconsistencies are detected, the data
is sent back to the reporting institutions for revision and
correction. In addition, according to the existing regulation
several specific projects are carried out to improve primary
data sources in order to guarantee a better quality of data
received. The SISPRO registers the primary diagnostic code
of the healthcare visit of both primary care and hospital
care visits. Data on healthcare services provided to DM
patients of the SISPRO for the years 2009–2012 were obtained
in October 2013 using the ICD10 codes E100–E149, G590,
G632, H280, H360, M142, N083, O240–O244, and O249.
Many DM patients contact the primary healthcare system
at very advanced stage of their disease presenting already
complications of DM. These patients are usually registered
with an ICD-10 code related to complications of DM as
primary diagnostic code. Therefore, we have included these
ICD-10 codes in our search to ensure that otherwise invisible
cases of DM were included in the analysis. In addition, the
ICD-10 differs between insulin-dependent DM (E10) and
non-insulin-dependent DM (E11). However, since a large
proportion of patients with type 2 diabetes are treated with
insulin, they are coded as E10. In addition, the ICD-10 codes
E12, E13, or E14 refer to unspecified DM. The consequence
of this is that the ICD-10 codes do not allow a genuine
and credible classification of clinical types of DM at least in
Colombia.
The CAC is an agency established by the Colombian State
in 2008 andmanaged by the healthcare insurance companies.
The objective of the CAC is to monitor high cost illnesses
within the Social Security Health System (SSHS) in order
to develop mechanisms for financial management and to
promote riskmanagement in relation to high-cost illnesses [7,
8]. By law, the healthcare insurance companiesmust report all
cases of DM, hypertension, and chronic kidney diseases that
occur within their healthcare users. The CAC register covers
90% of the Colombian population. In this study, information
of all identified cases of DM was received from CAC for the
years 2009, 2010, 2011, and 2012 [9–12].
It is important to mention that both of the above men-
tioned registers only provide information about DM cases
that have required healthcare attention. Thus, DM cases that
have not been in contact with healthcare services do not enter
the official registries. In addition, there is no data available in
regard to the type of DM.
Information regarding population size and projections
was retrieved from the National Administrative Department
of Statistics (DANE).DANE is the organization that processes
and shares the official Colombian population statistics [13].
DANE has also been considered as the official source of
information about mortality and some health indicators in
Colombian [14, 15].
2.1. Statistical Analysis. Age-standardized reportedDMprev-
alence rates per 100.000 inhabitants for the population of 20–
79 years of age from 2009 to 2012 were calculated separately
for the SISPRO and the CAC registers as a quotient: The
numerator was number of cases of DM in people 20–79
years of age in the SISPRO and, respectively, CAC register,
whereas the number of inhabitants aged 20–79 years reported
DANE population projections were used as the denominator.
The EpiDat software version 4.0 was used to standardize
the reported DM prevalence rates according to age using
as reference population estimated for Colombia for 2010
according to United Nations population. The estimation of
age-standardized reported DM prevalence rates for each
of the six regions (Figure 1) corresponds to the average
age-standardized rates calculated for the provinces in each
region. The age-standardized reported DM prevalence rates
are presented per 100.000 people for the age range 20–79
years.
The statistical analyses for time trends were performed
with SPSS forWindows 14.0.They were tested first for linear-
ity using Mantel-Haenszel test and for statistical significance
the Chi-square test was used. The trends in prevalence were
subsequently calculated using the linear regression model
log(PR) = 𝑎 + 𝑏𝑡 + 𝑒, where PR refers to prevalence, 𝑡 is time,
𝑒 is the error term, and 𝑎 and 𝑏 are the regression coefficients
estimated from the data. The change in prevalence per year
at the time point 𝑡 is a constant proportion, 100𝑏 percent
of the prevalence at 𝑡. The estimated average yearly change
in percent is exp(𝑏) − 1, which is approximately 𝑏 for small
changes. 100 ∗ exp(𝑏) is presented in the tables. The level of
statistical significance was set to 0.05.
Finally, for the maps presented in Figures 2(a), 2(b),
2(c), and 2(d), the annual reported DM prevalence rates of
each province were categorized into five categories according
to the performance in regard to the reported number of
DM patients compared to the highest national reported DM
prevalence rates (1593/100.000 in 2012) in the study period.
The categories were as follows: (i) higher than or not more
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Figure 1: The six regions of Colombia and its provinces.
than 19% lower than the highest national value of 2012
(≥1592,6/100.000); (ii) 1–20% lower than the national value
of 2012; (iii) 21–40% lower than the highest national value
of 2012; (iv) 41–60% lower than the highest national value of
2012; and (v) ≥60% lower than the highest national value of
2012, respectively.
3. Results
The trends of reportedDMprevalence rates in each region are
presented in Table 1. Both registers showed a statistically sig-
nificantly linear increase in reportedDMprevalence rates per
100.000 people during 2009 and 2012. Whereas the reported
DM prevalence rates of SISPRO revealed an increase from
964/100.000 inhabitants (2009) to 1398/100.000 inhabitants
in 2012 (mean annual increase 141/100.000;𝑝 value: 0.001), the
respective rates in the CAC register were 1082/100.000 (2009)
and 1593/100.000 in 2012 (mean annual increase 165/100.000;
𝑝 value: 0.026). The CAC register reported between 12% and
19% more DM cases/100.000 inhabitants compared to the
rate provided by the SISPRO register. This difference did not
statistically significantly change between 2009 and 2012.
Table 1 shows the age-adjusted reported DM prevalence
rates per 100.000 inhabitants 20–79 years old in the different
regions of Colombia according to the SISPRO and the CAC
register during 2009 to 2012. The reported DM prevalence
rates calculated from SISPRO reported a statistically sig-
nificant increase in the Andes region (𝑝 value: 0.002), the
region of Orinoco (𝑝 value: 0.039), and the Pacific region
(𝑝 value: 0.020) during the time period, whereas the DM
prevalence rates calculated fromCAC register had a statistical
significant linear increase in the age-adjusted reported DM
prevalence rates in the regions Andes (𝑝 value: 0.022), Pacific
region (𝑝 value: 0.004), and Bogota DC (𝑝 value: 0.035).
Both registers identified more DM cases/100.000 inhabitants
in 2012 compared to 2009. However, the annual increase in
DM rate ranged from 26 to 153/100.000 people in the SISPRO
register and from 25 to 203/100.000 inhabitants in the CAC
register, respectively.
As during 2009 and 2012 the reported DM prevalence
rates of CACwere regularly higher than the ones provided by
SISPRO, the changes in the reported DM prevalence rates of
the different provinces are only shown for the CAC register.
Figures 2(a)–2(d) present the development of the DM cases
reported in the CAC register in the different provinces of
Colombia during 2009 and 2012 compared to the national
reference value of 2012 (1593/100.000). Whereas 13 provinces
reported DMprevalence rates 80% or lower than the national
reference value in 2009, only eight provinces remained that
far away from the national reference value in 2012. Mainly,
the four provinces in east of the country, Choco at the Pacific
coast, and La Guajira in the north-east upper corner of
Colombia did not show any improvement in detecting DM
cases. Whereas in 2009 the reported DM prevalence rates
of 21 provinces were below 60% of the national reference,
the respective number in 2012 was 13 provinces. The number
of provinces reporting at least the national reported DM
prevalence rates of 2012 increased from two in 2009 to ten
in 2012.
4. Discussion
Our study showed that the registries and the information
retrieving system of SISPRO and CAC have been improved
during 2009 and 2012 resulting into a greater capacity to
identify and report DM cases by the healthcare system.
However, some regions and provinces showed a slower or
no increase in the reported DM prevalence rates creating a
future challenge for the official healthcare information system
of Colombia.
There are several possible reasons for the findings of our
study. First, the capacities of the registers to identify the DM
cases may have improved due to implementation of different
screening or early diagnosis activities within the healthcare
providers to detect people with DM. For instance, many
healthcare insurance companies have recently implemented
different benchmark system to catch DM patients as early as
possible to offer efficient treatment, whereas others may use
diabetes risk factors scores combined with laboratory tests
[16]. As there is a growing awareness of the burden of DM in
Colombia, many DM screening programs will be developed
in Colombia in the next years that may lead to a further
4 International Journal of Endocrinology
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Figure 2: (a) Reported DM prevalence rates (CAC register) of the different provinces of Colombia in 2009 compared to the best national
reported DM prevalence rate (1593/100.000). (b) Reported DM prevalence rates (CAC register) of the different provinces of Colombia in 2010
compared to the best national reported DM prevalence rate (1593/100.000). (c) Reported DM prevalence rates (CAC register) of the different
provinces of Colombia in 2011 compared to the best national reported DM prevalence rate (1593/100.000). (d) Reported DM prevalence rates
(CAC register) of the different provinces of Colombia in 2012 compared to the best national reported DM prevalence rate (1593/100.000).
increase inDMrates 13 detected by the healthcare system [17].
Generally, once individuals are diagnosed, approximately
50% are treated with medication, both in developed and
developing countries [18].
A second reasonable interpretation of our results may be
that the diabetes incidence has increased during the past four
years in Colombia. Both obesity and physical inactivity are
two of the most important risk factors for DM. Given the
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increased prevalence of obesity between 2005 and 2010 in
the Colombian adult population combined with low levels of
physical activity thismay be a reasonable explanation [19, 20].
The National Survey of the Nutritional Situation (ENSIN) of
2010 revealed that 35% of women and 34% of men 18–64
years of age were overweight. The corresponding prevalence
for obesity was 20% (women) and 11.5% (men). Further-
more, only every second 18–64-year-old adult reached the
current physical activity recommendations of 30 minutes of
daily moderate intensity physical activity [20, 21]. Thus, the
unfavorable development of the major risk factors of DM
may be reflected in the increase in the DM rates of people
with DM in the healthcare system. However, we would like
to point out that the data present here is not a study on
the true prevalence of DM in Colombia but rather about
the capacity to report DM cases by the healthcare system.
According to available evidence, every second a diabetes case
has not been diagnosed.The government has put an emphasis
on improving these registries in the past years obliging the
healthcare providers to improve disease reporting by a series
of new legislation. Thus, we think that the increase in the
reported DM prevalence rates can rather be explained by
the improved capacity of the healthcare system to detect
previously unknownDM cases than an increasing prevalence
of DM.
It has to be pointed out that the observed increase in
reported DM cases in the Colombian population may be
related to a better and easier access or higher demand to
healthcare for DM patients leading to higher DM rates
recorded in the reporting system. Furthermore, we hypoth-
esize that the difference observed between the regions in
regard to reported DM prevalence rates may be due to
the geographical distances from the more developed urban
centers. Probably, the access to healthcare services is more
difficult and the healthcare provider’s information systems
may have poorer development compared to the more devel-
oped regions of the country.
The IDF reported a DM prevalence of 7.05% in Colom-
bia [1]. Thus, there is a remarkable gap between the IDF
estimation and the DM prevalence found by the Colombian
National Health Survey [2] in 2007 (3.59%). Besides, con-
sidering that there are about 800 000 known DM patients in
Colombia, it is of great concern that only 50% of them get
admitted in the healthcare system.
Naturally, our study has some limitations.Thedata base of
SISPRO only registers the primary diagnostic code leading to
an underestimation of DM cases as some patients may have
DM as underlying condition to other diseases. In addition,
our analysis is restricted to the DM cases officially reported
and does not reflect the true prevalence of DM rather than
the DM cases that have been in contact with the healthcare
system. However, the objective of our study was not to
estimate the true DM prevalence but to report the DM
prevalence rates of the official information sources of the
healthcare system. Finally, the DM type and the treatment
profile that these registered patients are receiving are not
described by these sources. In any case, these two registers
are the only available sources of information in regard to the
number of treated DM patients in Colombia as the country
does not count with an official register for DM1 or DM2 at
the present moment.
5. Conclusions
The official information sources to track DM patients have
improved their ability to detect and record DM patients in
Colombia. However, many regions are still lacking behind the
national reference showing lower DM detection rates. The
future challenge for the Colombian healthcare system is to
identify DM patients as early as possible and provide equal
access to treatment as early as possible to decrease the burden
of DM.
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